Experiences with

Remdesivir

[/i] [i]Several COVID-19 treatments -- nirmatrelvir/ritonavir (Paxlovid), remdesivir (Veklury), and molnupiravir (Lagevrio) -- are expected to work against currently circulating variants, and are approved or authorized to treat patients with mild-to-moderate COVID-19 who are at high risk for progression

Monoclonal antibody or Remdesivir was not offered, and the next suggested step is going back to ED when I am in my death bed. Considering my age (over 65) and pre-existing Leukemia, and having COVID and pneumonia, it's astonishing that I'm not classified as a critical patient.

He came down with covid about two weeks ago, had three days of remdesivir that started 7 or 8 days after infection. He still has a terrible phlegmy cough and is constantly coughing up mucous. He’s been under a lot of stress lately too which seems to be making it worse.

I tested positive for covid on 1/10 and was coughing nonstop, fever, headache….they gave me 3 infusions of remdesivir, they said the paxlovid oral med was not a good fit with my meds.

We are left with two antivirals that are authorised to be given within 5 days of onset of symptoms - Paxlovid and Molnupiravir - and one within 7 days - Remdesivir.

Paxlovid must be started orally within five days of symptom onset and Remdesivir must be started intravenously within seven days of symptom onset. Wear a well-fitted N95 mask (or KN95) while around others who live outside of your household at all times.

We still have the powerful oral antiviral Paxlovid and the outpatient option of receiving IV Remdesivir. Also, we have the new bivalent vaccine, https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-updated-clinical-data-omicron?

Antiviral medications Paxlovid™ (nirmatrelvir/ritonavir), Legevrio™ (molnupiravir), and Veklury® (remdesivir) remain active against currently circulating COVID virus subvariants.

Antiviral medications Paxlovid™ (nirmatrelvir/ritonavir), Legevrio™ (molnupiravir), and Veklury® (remdesivir) remain active against currently circulating COVID virus subvariants.

The treatment continued with intravenous antibiotics, intravenous dexamethasone, and finally 5 days of remdesivir. After 4 days, the fever stopped and I was finally discharged from the hospital after 10 days. Treatment at home continues with oral antibiotics and prednisolone.

Interim-clinical-commissioning-policy-Therapies-for-symptomatic-non-hospitalised-patients-with-COVID-19-clinic.pdf wherein: "Consider access to this clinical pathway for patients under the following conditions: - Onset of symptoms of COVID-19 within the last 5 days (for nirmatrelvir/ritonavir1, sotrovimab and molnupiravir) or 7 days (for remdesivir

This could be either sotrovimab or nirmatrelvir with ritonavir (Paxlovid), and those who are unable to receive these treatments will be offered remdesivir (Veklury) and then molnupiravir.

I registered my condition with all the relevant departments and awaited a phone call from a doctor to assess my condition with the view to being offered one of the new treatments, (Nirmatrelvir, Ritonavir, Remdesivir, or Molnupiravir) because I am clinically extremely vulnerable.

A study featuring monoclonal antibody treatments (mAbs) Sotrovimab, Evusheld et al, and antiviral treatments Molnupiravir, Remdesivir and a Pfizer antiviral in development (not Paxlovid).

While there I was given Remdesivir intravenous (about 90 minutes at a time) for five consecutive days. I came out the other side, okay. If the risk versus reward balance is fairly clear I am going for anything and everything. Hope this helps someone else on this site.

The group on Remdesivir had a calculated reduction in risk of 87 %. The second https://www.nejm.org/doi/full/10.1056/NEJMe2118579?

My brother is being treated with Remdesivir for the antiviral, he is intubated and 3 days in ICU. The updates are very vague, "he is comfortable" etc.. I want to know how we can step in if the treatment is just going nowhere and ask for another drug if required.

Of the drugs that prevented the coronavirus from replicating in human cells, 19 were found to work in concert with or boost the activity of remdesivir, an antiviral therapy approved for treatment of COVID-19.

Notably, this technology enables scientists to investigate how various COVID-19 therapies, such as remdesivir, impact the replication of the virus. Their results are published in Proceedings of the National Academy of Sciences. "We believe that it is a true innovation," said Y.

The medical agents include raloxifene, a drug for osteoporosis, remdesivir, an antiviral drug approved in Japan as a COVID-19 treatment, and pioglitazone, used to treat diabetes.